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Abstract
Background: The impact of axial spondyloarthritis (axSpA) is considerable in many aspects of the life. Over the last
decades, many efforts have been conducted to develop useful tools for the evaluation of disease activity. However,
since the development of Assessment of SpondyloArthritis international Society Health Index (ASAS HI), no specific
freely questionnaire to describe the overall picture of impairments, limitations and restrictions in activities or social
partecipation were available. The aims of this study were to test the feasibility, reliability, and construct validity of
the ASAS HI, in order to compare its clinimetric properties with the current available measures of disease activity,
functional limitation and health status assessments in patients with axSpA.
Methods: A cohort of 140 consecutive axSpA has been the object of study. The feasibility has been determined by the
percentage of patients who were able to complete the questionnaire by themselves and by the time employed to fill
the ASAS HI. The reliability has been evaluated performing a test-retest of the questionnaire within a week. The
construct validity was examined in three ways. First, we examined construct convergent validity by correlating the
scores of the ASAS HI with the Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP/ESR, the Simplified
Ankylosing Spondylitis Disease Activity Score (SASDAS), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),
the Bath Ankylosing Spondylitis Metrology Index (BASMI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the
Ankylosing Spondylitis Quality of Life scale (ASQoL) and the EuroQoL Five Dimensional Questionnaire (EQ-5D). Secondly,
we have created patient groups based on the patients' activity ranks (ASDAS-CRP and SASDAS categorisation) within the
cohort to assess discriminative accuracy. Additionally, to distinguish patients with active and non-active disease and to
assess their respective cut-off points values, the receiver operating characteristic (ROC) curve analysis was used. Thirdly, we
analyzed the contribution of demographic (age, sex, and disease duration) and clinical variables (number of comorbidity
and disease activity by ASAS-CRP) to the attainment of an ASAS HI condition by stepwise logistic regression.
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Results: The mean time to complete the ASAS HI was 1.92 ± 0.76 min. Overall, the ASAS HI questionnaire was correctly
completed by the majority of the patients (99,2 %). Coefficients of agreement between ASAS HI scores on first and
second administrations were excellent and all items showed very good agreement (ICC = 0.976; range 0.966 to 0.982). The
ASAS HI was correlated significantly with all other comparator scores (p <0.0001). The highest correlations were seen with
ASQoL (rho 0.784; p <0.0001), BASFI (rho 0.671; p <0.0001) and SASDAS (rho 0.640; p <0.0003). On categorizing patients
into different cut-off point of disease activity, with respect to the both ASDAS-CRP and SASDAS, ASAS HI scores were
highly significantly different between the four categories (p <0.0001). An ASAS HI value of 4.0 resulted the cut-off with the
highest combination of sensitivity and specificity (82.6 % and 86.3 %, respectively) to define the inactive disease. In the
logistic regression model, high disease activity measured by ASDAS-CRP (coefficient 2.39; p <0.0001), was the only
independent variable associated with ASAS HI.
Conclusions: The results reported in this study confirm the feasibility, reliability and validity of the ASAS HI in Italian
patients with axSpA. Even if ASAS HI is not a disease activity index, of particular interest appears the cut-off value of 4.0,
under which could be defined the inactive disease. This value could represent an easily applicable starting point in daily
clinical practice.
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Background
Axial spondyloarthritis (axSpA) include diseases with pre-
dominantly axial involvement, such as ankylosing spon-
dylitis (AS), psoriatic arthritis (PsA) and non-radiographic
axial SpA (nr-axSpA) which have as key symptoms
both inflammatory back pain and stiffness [1–3].
The impact of AS and nr-axSpa in many aspects of life
is considerable, not only about pain, fatigue, stiffness,
limitation in activities and in social partecipation, but
also in terms of concern about the appeareance, the
future and the medication side effects [4, 5].
Over the last decade, significant progresses have been
achieved in the development and validation of new tools
for the evaluation of disease activity in axSpA [6, 7].
Most of them are based on self-reported questionnaires,
such as the Bath Ankylosing Spondylitis Disease Activity
Index (BASDAI) [8], which is the more frequently used
in clinical trials, or the AS Disease Activity Score
(ASDAS) [9], recently proposed by a working Group of
the Assessment of SpondyloArthritis international Soci-
ety (ASAS) for the evaluation of disease activity in pa-
tients with AS. ASDAS is the first validated disease
activity system that combines both patient-reported out-
come (PRO) measures and acute-phase reactants levels.
Sommerfleck et al. developed a simplified version of the
ASDAS, named Simplified Ankylosing Spondylitis Dis-
ease Activity Score (SASDAS) [10]. This score, keeping
the sensitive characteristics of the ASDAS, can be con-
sidered an intuitive and easy way to assess the disease
activity in patients with axSpA.
Thus, while in axSpA are disposable instruments to
measure disease activity, but also radiographic damage
[11], and magnetic resonance imaging (MRI) inflamma-
tion [12], no specific freely available questionnaires to
describe the overall picture of impairments, limitations
and restrictions in activities or social partecipation
were at hand since the creation of ASAS Health Index
(ASAS HI) [13]. This tool has been recently developed
by Kiltz et al. [13, 14] to assess health in patients with
AS according to the International Classification of Func-
tioning, Disability and Health (ICF) categories [15]. The
17 statements of ASAS HI have been obtained from a
pool of 251 items originating from questionnaires
already in use for patients with axSpA or from question-
naires linked to the ICF. These statements address to
the ICF categories of pain, emotional functions, sleep,
sexual function, mobility, self-care and community life.
So ASAS HI can provide information about the whole
range of common difficulties experienced by patients
with axSpA [13]. The ASAS HI has been translated into
15 languages, including the Italian.
Taking into account these informations we addressed
the aims of our study in the following points: to test the
feasibility, reliability, and construct validity of the ASAS
HI in order to define its clinimetric properties and to
compare its discriminant validity with the current avail-
able measures of disease activity, functional limitation
and health status assessments in patients with axSpA.
Methods
Patient characteristics
From May 2015 to October 2015 have been enrolled 140
consecutive axial SpA patients. The classification of
axSpA was based on fulfillment of the ASAS classifica-
tion criteria that are defined as follows: the presence of
sacroiliitis by radiography or by MRI plus at least one
SpA feature (“imaging arm”) or the presence of HLA-
B27 plus at least two SpA features (“clinical arm”) [2, 3].
Exclusion criteria were the following: other active con-
comitant musculoskeletal diseases (e.g. gout, calcium
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pyrophosphate dyhidrate crystal deposition, rheumatoid
arthritis), history of cancer or lymphoproliferative dis-
ease, uncontrolled diabetes, unstable ischemic heart dis-
ease, congestive heart failure, active inflammatory bowel
disease, positive serology for hepatitis B, history of active
tuberculosis and concomitant fibromyalgia. All patients
were treated with non-steroidal antiinflammatory drugs
on an on-demand basis. A total 99 patients were on
TNF-blockers (70.7 %), including infliximab (39 pa-
tients), adalimumab (27 patients), etanercept (22 pa-
tients), golimumab (nine patients) and certolizumab
pegol (two patients). The choice of the TNF blocking
agent was based on the judgment of the rheumatologist
and/or on the specific needs of the patient. Patients were
allowed to receive concomitant medications as usual in
daily clinical practice. All patients were attending the
outpatient and inpatient clinics of the Rheumatology De-
partment of the Polytechnic University of the Marche
(Jesi, Ancona, Italy) and they represent a “real life” sam-
ple of axSpA. The study was approved by the Hospital
Clinic ethics committee. All patients agreed to be en-
rolled in the study and signed informed consent. During
the routine visits to our Clinic, a comprehensive ques-
tionnaire package has been administered to the patients.
The package included the socio-demographic data (sex,
age, disease duration and years of school attendance),
the ASAS HI [13], the Bath Ankylosing Spondylitis Dis-
ease Activity Index (BASDAI) [8], the Bath Ankylosing
Spondylitis Functional Index (BASFI) [16], the EuroQoL
Five Dimensional Questionnaire (EQ-5D) [17], and the
Ankylosing Spondylitis Quality of Life Scale (ASQoL)
[18]. The presence of the following co-morbidities was
also assessed: hypertension, myocardial infarction, lower
extremity arterial disease, major neurological problems,
diabetes, gastrointestinal disease, chronic respiratory dis-
ease, kidney disease, and poor vision. The ESR (mm/
hour) and CRP serum levels (mg/dl) were also collected.
All patients gave their informed verbal consent for
anonymous analysis of data.
ASAS HI questionnaire
The ASAS HI questionnaire is composed by 17 items,
expressed in the the first person and in present tense,
with dichotomous response option: “I agree” and “I do
not agree”. Each positive answer is scored 1 while a
negative answer is scored 0. The final result is the sum
of individual items. Higher values reflect a major degree
of impairments, limitations and restrictions. For ASAS
HI questionnaire has been performed a re-test: each pa-
tient has been invited to fill in for a second time the
ASAS HI at home within 1 week from the first adminis-
tration. This re-test has been handed over during the
consecutive visit to our Clinic. In our cohort of patients
has been used the online available ASAS HI Italian
translation [19].
Other functional limitation and health status assessments
The Bath Ankylosing Spondylitis Metrology Index
(BASMI) quantifies the mobility of the axial skeleton in
AS patients and allow objective assessment of clinically
significant changes in spinal movement. It includes clin-
ical measures of cervical rotation, tragus to wall distance,
lumbar flexion, lumbar side flexion, and intermalleolar
distance. Each item is scored from 0 to 10 based on indi-
vidually defined cut-points. Ranges are given as cervical
rotation (>85.0° to <8.6°), tragus to wall distance
(<10 cm to >36 cm), lumbar flexion (>7.0 cm to
<0.8 cm), lumbar side flexion (>20.0 cm to <1.2 cm),
and intermalleolar distance (>119 cm to <30 cm) [20].
Individual scores are averaged to give a final score
between 0 and 10, where a higher value reflects more
significant impairment of spinal mobility.
The BASFI is composed by ten questions elaborated to
determine the degree of functional limitation in patients
with AS. Each question is answered using an 11-points
numerical rating scale (NRS), with a recall period of the
past week. The mean of the ten scales affords the BASFI
score – a value between 0 and 10, with a lower score
indicating less functional limitation [16]. In this study
the paper formats previously validated in the Italian
language of the BASFI and the BASDAI have been
employed [21].
The ASQoL measure the impact of AS on health-
related quality of life (HRQoL) from the patient’s per-
spective [18]. The questionnaire includes items related
to the impact of disease on sleep, mood, motivation,
coping, activities of daily living, independence, relation-
ships, and social life. Dichotomous responses, with 0
scored for a “no” and 1 scored for a “yes” for each item.
Total score is the sum of the individual responses. Score
range is 0–18, with higher scores reflecting greater
impairment of HRQoL.
The EQ-5D health state classifier consists of five
single-item dimensions - mobility, self-care, usual activ-
ities, pain/discomfort, and anxiety/depression - with
three levels of response for no, some, or extreme prob-
lems in each dimension [17]. In addition to the health
state classifier, patients rated their current health on a
20-cm visual analog scale (EQ-5D VAS) ranging from 0
(worst possible health state) to 100 (best possible health
state). Responses to these five dimensions are converted
into one of 243 different EQ-5D health state descrip-
tions, which range between no problems on all five
dimensions (11111) and severe/extreme problems on all
five dimensions (33333). The Italian population-based
values were used to convert patient responses to the
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health state classifier into a single index, which produces
scores from 1 to − 0.38 [22].
Measures of disease activity
The BASDAI has six 11-points NRS to measure the
severity of fatigue, spinal and peripheral joint pain, local-
ised tenderness, and morning stiffness in patients with
AS. Each item is provided using a 0–10 horizontal NRS,
to extremes the adjectival descriptors “none” and “very
severe”. Item six (duration of morning stiffness) is
related to a time scale (0–2 h). The mean of items five
(severity of morning stiffness) and six is calculated sep-
arately. The BASDAI, a number from 0 to 10, is
obtained with the mean of this result with the previous
four items. Lower score are indicating lower disease
activity. The cut-off of four is used to define the pres-
ence of an active disease [8].
The ASDAS is a composite index to measure disease ac-
tivity in AS, including both self-reported items and objective
measures [9]. The score includes assessment of back pain
(question 2 of BASDAI), duration of morning stiffness
(question 6 of BASDAI), peripheral joint pain and/or swell-
ing (question 3 of BASDAI), PaGA, and a serologic marker
of inflammation (ESR or CPR). Five items are combined to
give a single disease activity score. The ASDAS has been
validated and found to be discriminatory in assessing disease
activity in axSpA and it has been endorsed by the ASAS
and by the Outcome Measures in Rheumatology (OMER-
ACT). The published cut-offs of ASDAS are the following:
<1.3 for inactive disease, ≥1.3 and <2.1 for moderate disease
activity, ≥2.1 and <3.5 for high disease activity and ≥3.5
for very high disease activity. A gain ≥1.1 units is considered
as a “clinically important improvement”, while an amelior-
ation ≥2.0 represents a “major improvement” [23, 24].
The SASDAS is a simplified version of ASDAS devel-
oped by Sommerfleck et al. and can be considered an
intuitive and easy way to assess the disease activity in
patients with AS [10]. While the equation used to calcu-
late the ASDAS is relatively complex (since requires a
calculator), SASDAS can be quickly assessed in the busy
daily clinical practice showing a similar good discrimina-
tive ability and correlation with different constructs of
disease activity and health status compared to the
ASDAS [25].
Statistical analysis
Continuous data were presented as means with standard
deviations (SDs) or medians with interquartile range)
depending on the distribution of the data (tested with
the Kolmogorov–Smirnov test). Categorical data were
presented as proportions. Demographic and clinical
measures were compared using Mann–Whitney “U” test
and chi-square analysis for discontinuous variables. To
check for significant systematic differences in test-retest
administration, intraclass correlation coefficients (ICC)
with 95 % confidence intervals (95 % CI) for mean
values were employed. ICC >0.75 were considered rele-
vant [26]. The operational qualities or the feasibility of
ASAS HI questionnaires were investigated by the per-
centage of patients who were able to complete the ques-
tionnaire by themselves and by the time employed in
filling it out. Within a 1-week interval, patients were
asked by the same data collector to repeat ASAS HI,
without having access to any previous ratings. Consider-
ing the possibility of a change in the patient’s condition
over a 1-week interval, a global rating-of-change ques-
tionnaire was concurrently administered to the subjects.
This so-called “transition questionnaire” investigated the
patient’s current health status compared with that when
the first questionnaire was completed (question: “com-
pared to when you completed the questionnaire regard-
ing your health status a week ago, how is your health
now?”). Possible response options were “much better”,
“slightly better”, “no change,” “slightly worse,” or “much
worse”. Subjects who reported no change were consid-
ered stable and those who reported a change were elimi-
nated from this analysis. In this study, test-retest
reliability was analyzed in a group of 125 patients who
reported no change in their health. Agreement between
scores was also illustrated by Bland and Altman plots, in
which the difference between scores was plotted on the
y-axis against the average of scores on the x-axis. The
construct validity of the ASAS HI was examined in three
ways. First, we examined construct convergent validity
by correlating the scores of the ASAS HI with ASDAS-
CRP/ESR, SASDAS, BASDAI, BASMI, BASFI, ASQoL
and EQ-5D. A specific subscale is expected to converge
with the scores of those instruments targeting the same
construct and to deviate from the scores given by instru-
ments or scales assessing a different one (divergent
validity). Spearman’s rho correlation coefficients were
obtained to quantify these relationships. Correlations
>0.90 were interpreted as very high, 0.70–0.89 as high,
0.50–0.69 as moderate, 0.26–0.49 as low and ≤0.25 as
little if any correlation occurred. Secondly, we explored
the discriminative accuracy of the ASAS HI question-
naire. For this purpose, we have created patient groups
based on the patients’ activity ranks within the cohort
and used Kruskal-Wallis test for continuous variables to
assess differences. The ASDAS-CRP scores were cate-
gorised into four groups: <1.3 for inactive disease, ≥1.3
and <2.1 for moderate disease activity, ≥2.1 and <3.5 for
high disease activity, and ≥3.5 for very high disease ac-
tivity [23]. Similarly, the SASDAS scores were cate-
gorised into four groups as follows: inactive disease from
0 to 7.8 (inactive disease), from 7.9 to 13.8 (moderate
disease activity), from 13.9 to 27.6 (high disease activity),
and above 27.6 (very high activity) [10]. Additionally, to
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distinguish patients with active and non-active disease
and to assess their respective cut off points values, the
receiver operating characteristic (ROC) curve analysis
was used. The criteria for inactive disease for ASDAS
and SASDAS were applied as external criteria. ROC
curves were created by plotting the true-positive propor-
tion (sensitivity) versus the false-positive proportion
(100-specificity) for the discrimination between inactive
and active patients for multiple cut-off points. The area
under the ROC curve (AUC) was calculated to quantify
the discriminative accuracy. According to Swets [27],
AUC from 0.50 to about 0.70 represent poor accuracy,
those from 0.70 to 0.90 are “useful for some purposes”,
and higher values represent high accuracy. From the
ROC curves, we computed the optimal cut off point
corresponding to the maximum sum of sensitivity and
specificity. The non-parametric Wilcoxon’s signed ranks
test is used for calculation and comparison of the areas
under the ROC curves, as suggested by Hanley and
McNeil [28]. Finally, we analyzed the contribution of
demographic (age, sex, and disease duration) and clinical
variables (number of comorbidity and disease activity by
ASAS-CRP) to the attainment of the ASAS HI condition
by stepwise logistic regression. Others clinical variables
such as BASMI, BASFI, BASDAI, SASDAS, ASQoL and
EQ-5D were excluded for collinearity. All data were en-
tered into a Microsoft Excel database which was devel-
oped for the management of the cross-sectional study.
All the statistical analyses were performed using the




The mean age of the 140 patients examined was 46.2 ±
12.0 years (range 22–77). One hundred and one of the
respondents were male (72.1 %), 39 were female
(27.9 %). The mean duration of disease was 6.7 ±
4.8 years. Ninety-eight patients (70.0 %) had AS while 42
(30.0 %) had nr-axSpA. The mean value (SD) of ASDAS-
CRP was 2.2 (0.9), in the range of high disease activity,
as long as the mean (SD) BASDAI resulted 3.5 (1.8).
The mean values (SD) of BASMI, BASFI and ASQoL
were respectively 3.1 (2.1), 3.6 (2.4) and 7.9 (5.1) (see
Additional file 1). The 48.5 % had receveid a primary
school education and 19.5 % had receveid a high school
education. At baseline, 111 patients (79.3 %) had one or
more concurrent diseases. The most commonly re-
ported diseases were hypertension (71 patients, 50.7 %)
and metabolic disorders (40 patients, 28.6 %). Regard-
ing the extra-articular manifestations, 15 patients
(10.7 %) had a simultaneous inflammatory bowel
disease, respectively ten patients (7.1 %) Crohn disease
and five patients (3.6 %) ulcerative colitis, while 11
patients (7.9 %) had at least one episode of anterior
uveitis.
Score distributions of the ASAS HI
Figure 1 presents estimates of central tendency and dis-
tribution of score for ASAS HI in all patients at baseline
(n = 140 patients). The bar on the left of each graph rep-
resents the number of subjects with a score of 0 (floor
effect); the bar on the right represents the number of
subjects with a maximum possible score (ceiling
effect). ASAS HI showed a non-normal distribution.
The mean (SD) was 7.6 (3.9) and the median (IQR)
was 8.0 (4.5–11.0) (see Additional file 2).
Test-retest reliability and feasibility
Mean time between the questionnaire administrations
was 5.8 days (range 4–7 days). Coefficients of agreement
between ASAS HI scores on first and second administra-
tions were excellent. All items showed very good agree-
ment (ICC = 0.976; range 0.966 to 0.982). According to
Bland and Altman analysis, there was no systematic
error in ASAS HI and in scores (Fig. 2). The mean time
to complete the ASAS HI questionnaire by patients was
1.92 ± 0.76 min (range 0.8–3.5 min). Overall, the ASAS
HI questionnaire was correctly completed by most re-
spondents (99.2 %). Less than 1 % of each of the ASAS
HI questions had missing values. Only four patients
(2.9 %) refused to answer to the statement number 7
(interest in sex).
Concurrent validity
The ASAS HI was correlated significantly with all other
comparator scores (p <0.0001) (Table 1). The highest
Fig. 1 Histograms demonstrating the range and the distribution
of ASAS HI questionnaires values. The horizontal axis shows
the scores (range 0–17), with high scores indicating a worse
health status
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correlations were seen with ASQoL (rho 0.784; p
<0.0001), BASFI (rho 0.671; p <0.0001) and SASDAS
(rho 0.640; p <0.0003). Strong correlations were also
found with ASDAS-ESR (rho 0.580; p <0.0001), ASDAS-
CRP (rho 0.564; p <0.0001), BASDAI (rho 0.568; p
<0.0001) and EQ-5D (rho 0.460; p <0.0001). Moderate
correlation was found between ASAS HI and BASMI
(rho 0.303; p = 0.0001) (Table 1). With respect to the age
and disease duration, ASAS HI did not show any signifi-
cant correlation. Categorizing patients according to the
proposed ASDAS-CRP and SASDAS disease activity
scoring system revealed 23 patients (16.43 %) with
inactive disease, 36 patients (25.71 %) with moderate dis-
ease activity, 70 patients (50.00 %) with high disease ac-
tivity, and 11 patients (7.86 %) with very high disease
activity for ASDAS-CRP; 25 patients (17.86 %) with
inactive disease, 20 patients (14.29 %) with moderate dis-
ease activity, 83 patients (59.29 %) with high disease
activity, and 12 patients (8.56 %) with very high disease
activity for SASDAS. The cross-classification showed a
significant agreement (weighted Kappa 0.79 with stand-
ard error of 0.048). On categorizing patients into these
different cut-off point of disease activity, with respect
to the both ASDAS-CRP and SASDAS, ASAS HI
scores were highly significantly different between the
four categories (p <0.0001) (Fig. 3a and b) (Kruskal-
Wallis test).
Discriminant validity
The ROC curves to discriminate the ability of ASAS HI
to distinguish patients with active and inactive disease
were similar to ASQoL and BASFI (Table 2 and Fig. 4).
The discriminatory power of ASAS HI was very good,
without significant difference, with an AUC of 0.850
(95 % CI 0.763 ± 0.938) (differences between areas of the
ASQol = 0.053 ± 0.038 with 95 % C.I. from 0.022 to
0.128; p = 0.1691 and differences between areas of the
BASFI = 0.029 ± 0.045 with 95 % C.I. from 0.060 to
0.118; p = 0.521). From these data, we calculated the cut-
off values of ASAS HI for inactive disease with the
highest combination of sensitivity and specificity. The
Fig. 2 Bland-Altman plot of repeatibility with the differences in ASAS
HI values plotted against average values. Ninety-seven percent of the
differences against the means were less than two standars deviations
(SD; dotted lines)
Table 1 Convergent validity analysis: correlation matrix (Spearmanʼs rho) of the ASAS HI Questionnaire versus anthropometric measures
(BASMI), specific and generic HRQoL questionnaires (ASQoL and EQ-5D), functional disability (BASFI) and disease activity scores
(BASDAI, ASDAS-CRP and SASDAS)
ASQoL BASDAI BASFI BASMI EQ-5D SASDAS ASDAS-CRP
ASAS HI 0.784 0.568 0.671 0.303 −0.460 0.640 0.564
<0.0001 <0.0001 <0.0001 0.0003 <0.0001 <0.0001 <0.0001
ASQoL 0.645 0.626 0.271 −0.436 0.689 0.620
<0.0001 <0.0001 0.0012 <0.0001 <0.0001 <0.0001
BASDAI 0.586 0.192 −0.453 0.868 0.757
<0.0001 0.0229 <0.0001 <0.0001 <0.0001
BASFI 0.578 −0.329 0.723 0.624
<0.0001 0.0001 <0.0001 <0.0001






Spearman rank correlation coefficient
Abbreviations: ASAS HI Assessment of SpondyloArthritis international Society Health Index, ASQoL Ankylosing Spondylitis Quality of Life Scale, BASDAI Bath
Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index,EQ-5D EuroQoL Five
Dimensional Questionnaire, SASDAS Simplified Ankylosing Spondylitis Disease Activity Index, ASDAS Ankylosing Spondylitis Disease Activity Score, CRP C-Reactive Protein
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resulting cut-off value was 4.0 (sensitivity 82.6 %; speci-
ficity 86.3 %) with a LR+ of 6.04 (see Additional file 3).
Variables associated with ASAS HI
In the logistic regression model (Table 3), high disease
activity measured by ASDAS-CRP (coefficient 2.39; p
<0.0001) was the only independent variable associated
with ASAS HI. Other predictors such as age, sex, disease
duration, educational level and comorbidity were not
clinically important contributors to questionnaire.
Discussion
The severity of axSpA is defined by different aspects of
the disease, such as disease activity, damage, reduced
motility, reduced physical function, reduced social parte-
cipation and work ability, with considerable costs,
frequently hidden and not easy to quantify [4, 5, 29].
Moreover, patients with problems due to extra-articular
organ involvement related to axSpa such as uveitis,
inflammatory bowel disease, and psoriasis, undergo to
additional disadvantages.
Data from clinical trials and observational cohorts
have shown that the burden of the disease in nr-axSpA
is comparable to that in patients with AS [30, 31]. In
our study we considered both patients affected by AS
and nr-axSpA.
Fig. 3 Distribution of ASAS HI scores in relation to different ASDAS-CRP
(a) and SASDAS (b) cut-off of disease activity. The figure shows the mean
values of ASDAS HI on the basis of disease activity cut-off points of
ASDAS-CRP (a) and SASDAS (b). The Kruskal-Wallis test was carried out
across all four groups (p <0.0001)
Table 2 AUC-ROC curve values (standard error and 95 %
confidence intervals) to distinguish patients with active and
non-active disease, were similar for ASAS HI, ASQoL and BASFI
questionnaires
AUC SEa 95 % CIb
ASAS HI 0.850 0.044 0.763 to 0.938
ASQoL 0.903 0.032 0.840 to 0.967
BASFI 0.880 0.046 0.790 to 0.969
BASMI 0.657 0.073 0.515 to 0.800
EQ-5D 0.656 0.062 0.534 to 0.778
For abbreviations see Table 1
aHanley & McNeil, 1982
bAUC ± 1.96 SE
Fig. 4 The ROC curves to discriminate the ability of ASAS HI to
distinguish patients with active and inactive disease in comparison
with anthropometric measures and self-report questionnaires, using
ASDAS-CRP as external indicator. The area under the ROC curve
(AUC) in this setting can be interpreted as the probability of correctly
identifying the improved patients from non-improved. A line that runs
diagonally across the figure from lower left to upper right will have an
area of 0.5; this represents an instrument that does not discriminate
Di Carlo et al. Health and Quality of Life Outcomes  (2016) 14:78 Page 7 of 9
A precise meaning of the severity of axSpA has to
include several categories. The core set of “what to
measure”, because it is typical and relevant for function-
ing and health in patients with AS, has been established
in 2010 by the ASAS on the basis of the ICF, published
by World Health Organition (WHO) [32]. ICF is a uni-
versally agreed and understood framework to define the
spectrum of problem in functioning. This classification
endorses the bio-psyco-social model, recognising the im-
portance of environmental and personal factors on func-
tionig and disability [15]. In the context of the ICF, the
term “functioning” belongs to a concept of health and
global functioning, wider than the physical function. In
clinical setting ICF is used not only for a functional sta-
tus assessment, but also for goal setting, treatment plan-
ning and monitoring, as well as outcome measurement.
ASAS HI has been developed with the purpose to
measure the overall picture of impairments, limitations
and restrictions due to AS.
Thus, while previous instruments have been focused
on specific symptoms, physical function and HRQoL
[16, 18], ASAS HI is the first PRO disease-specific, based
on the categories of ASAS/WHO comprehensive ICF
core set for AS [13]. The use of the ASAS HI seems
feasible in clinical practice, since it contains only 17
dichotomous items.
As described by our results, it is also a reliable tool, with
a strong agreement beetween two test within a week.
Even if ASAS HI is a health index and not a HRQoL
instrument, the highest correlation in terms of concur-
rent validity was found with ASQoL, one of the most
relevant questionnaire in the evaluation of QoL in pa-
tients with AS. A good concurrent validity has been also
found in comparison with the other indices, except
BASMI, that is an anthropometric measure [20].
Among the proposed indices to evaluate disease activity,
BASDAI is the most frequently used in clinical trials and
in daily practice as yet. However BASDAI could be and
ambiguos measure of disease activity that does not cap-
ture the entire spectrum of problems [33].
Respect to BASDAI, the ASDAS (or the simplified
SASDAS) is an index that reflects several aspects of
disease activity and correlates well with both physician’s
and patient’s perception of disease activity.
ASAS HI is not a measure of disease activity, notwith-
standing our data showed the capability of the instru-
ment to categorize the patients into different cut-off
point of disease activity, with respect to the both ASDAS
and SASDAS. Of particular interest appears the cut-off
value of 4.0, under this value patients could be defined
to have inactive disease. This value could represent an
easily applicable starting point in daily clinical practice
in patients with axSpA.
Moreover, for its features, we think that ASAS HI
could be usefully adaptable for electronic systems cap-
turing PROs [34], and this topic will be object of future
researchs.
The major limitations to this study are represented by
specific restrictions of each analytic method. A primary
limitation which must be emphasized is that responsive-
ness of ASAS HI has not been studied over a long period
of time. A further potential limitation that has to be
considered regarding the presented results is due to a
non-randomly selected primary care sample.
Conclusions
The results reported in this study confirm the feasibility,
reliability and validity of the Italian version of ASAS HI in
patients with axSpA. Although we have not yet studied
the sensitivity of ASAS HI to change (i.e., responsiveness),
this study has some implications for the conduction of fu-
ture clinical trials in axSpA. Its generalisability and useful-
ness in assessing treatment and long-term outcomes now
need to be evaluated in broader settings. Such kind of ana-
lyses are currently underway.
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